INTRODUCTION
Elevated maternal serum a-fetoprotein (AFP) levels in pregnancy are generally regarded as an indicator of open neural tube, ventral wall and other developmental defects in the foetus, and also of various problems of pregnancy. AFP, combined with serum levels of human chorionic gonadotrophin (hCG) and unconjugated oestriol (uE3), constitutes the`triple test' panel for the assessment of a baby's having a trisomy or triploidy. The most general applications are as an estimate of the risk of Down's syndrome due to trisomy 21, the most common congenital cause of severe mental retardation and, more recently, Edwards syndrome due to trisomy 18.
Each of the three analyte levels is reported in terms of its concentration as a multiple of its median level (MoM) in populations of unaffected singleton pregnancies at the physician-speci®ed completed week of gestation (cGW). Maternal age and the three MoM are incorporated into algorithms for calculating the Down's syndrome risk, the one most generally used being that of Cuckle, Wald and coauthors. 1, 2 It has long been known that the incidence of chromosome abnormalities is signi®cantly affected by the mother's age. Although the risk increases with age, particularly above age 35, more babies with these defects are born to younger mothers owing to the greater number of pregnancies in the younger age groups.
Nevertheless, in accordance with accepted screening practice, a patient with a risk 5 that of a 35 year old, i.e. approximately 1:270 at midtrimester and 1:380 at term, is considered`at risk'. Less than 1:380 at term is considered`not at risk' or, more reasonably,`low risk'.
It is not always appreciated that (1) the risks determined using the generally followed protocols are statistical in nature and do not indicate with certainty that a particular baby will or will not have Down's syndrome; (2) the protocols involve MoM which are`adjusted' for maternal diabetes and race using factors that do not relate to the individual patient but which are based on trends recorded in large, speci®cally de®ned and characterized populations; (3) strong reliance is placed on the accuracy with which the patient's cGW is determined. Ultrasound dating is most accurate in the ®rst trimester; however, for many reasons an initial ultrasound may not be performed until the second trimester. Ultrasound accuracy in the second trimester ± the period in which this test is used ± has been estimated as from +7 days to +10 days, a range of two to almost three weeks. 3, 4 Although many laboratories use day-rather than week-speci®c medians the most common practice appears to use week-speci®c medians, as only week of gestation (assumed to be completed week rather than truncated, i.e. rounded) is generally supplied by the obstetrics service. As a result, the analyte levels of, for example, a patient 15 weeks+6 days are related to the same 15-week medians as a patient 15 weeks+1 day, and not to 16-week medians. Clearly, a dating error of one day or a few days (within the accuracy level of ultrasound determinations pointed out above) could result in the use of 14-, 15-or 16-week medians, with substantial differences in reported risk.
The less than optimal accuracy of dating is also evident from the fact that the laboratory is frequently asked to recalculate a reported risk following a reassessment of a patient's gestational dating. In other cases a recalculation may not be requested at all if a change of 1±2 weeks is assumed to have little effect on a previously reported low risk. It is also not unusual for a second specimen to be submitted with a cGW inconsistent with that indicated for the ®rst specimen.
Williams et al. 5 have shown that the choice of algorithm and method of establishing medians may cause a signi®cant variation in reported Down's syndrome risk. The present study was an attempt to determine how risks calculated using one algorithm might be affected by inaccuracies of 1±2 weeks or more in gestational age. This entailed re-entering each patient's analytical data into the algorithm and determining the Down's syndrome risks using the medians, not only at the patient's original cGW but at each cGW from 15 to 20 weeks.
Whereas an algorithm involving serum AFP, hCG and oestriol is used to assess the risks of chromosome abnormalities,an elevation of serum AFP MoM alone is the basis of the most common biochemical screening test for open neural tube defects (oNTD). In pregnancy, serum (and amniotic¯uid) AFP is also increased in ventral wall, renal and numerous other developmental defects. The generally accepted`cut-offs' distinguishing`screen-positive' and`screen-negative' non-insulin dependent patients are a serum AFP 52´0 or 52´5 MoM, and 52´0 for patients who are insulin dependent. As AFP medians increase approximately15% per week during this period, it should be expected that oNTD screening results also would be affected by what might otherwise be considered insigni®cant dating errors.
METHODS
AFP was determined using an Abbott IMx, and more recently with an Abbott Axsym (Abbott Laboratories, Abbott Park, IL 60064). hCG originally was determined using an Abbott IMx, and more recently using a Bayer Immuno-1 (Bayer Corporation, Tarrytown, NY 10591). uE3 was determined by radioimmunoassay (Diagnostic Systems Laboratories, Webster, TX 77598). (Changes in analytical instruments were an administrative decision, not based on instrument accuracy or reliability. Analyte medians were calculated in accordance with accepted practice and were consistent despite instrument changes which affected neither the results reported to physicians nor the data collected for this study.)
All original routine reports of analyte levels, MoM and Down's syndrome risks had been generated and stored using this author's`PACE' software, an acronym for`Prenatal a-fetoprotein, chorionic gonadotrophin, oestriol'. 6 In accordance with accepted procedure, the program reports MoM ± appropriately adjusted for the patient's weight, race and insulin dependence ± and risk of trisomy 21. It also indicates graphically the likelihood of various conditions contributing to the patient's AFP results and reports the possibility of other conditions, including trisomy 18 and triploidy. Because it stores patient data, the report also includes the results of previous submissions and notes dating inconsistencies.
Data stored as PACE ®les were copied directly into a program that used the same risk algorithms to recalculate and tabulate each patient's risks at the original cGW, and at each week from 15 to 20 weeks, using the laboratory's established 15±20-week medians.
From patient data routinely processed during the most recent period prior to this study, the 378 were selected who had indicated Down's syndrome risks 41:500. Because in general a 1:380 term risk distinguishes between`low' and high', 1:500 or less would generally be accepted as low risk for Down's syndrome. Although patient ages ranged from 14 to 45 years, the mean was 24´9 (median: 24; mode: 23) years. Racial makeup was 54% black, 4% oriental, 42% caucasian; 4% were insulin dependent. All were reported to be singleton pregnancies.
Patients in this group were also oNTD screen positive or screen negative. The small screenpositive group consisted of 15 non-diabetic patients with AFP MoM 52´5, and ®ve insulin-dependent patients with AFP MoM 52´0. (Excluded were cases with extremely elevated AFP MoM, ranging from 5´1 to 8´6, which were associated with severe malformations and fetal demise.) Mean age was 27; median 26 years.
The screen-negative group consisted of 80 non-diabetic patients with MoM 1´5±2´4 and 10 insulin-dependent patients with MoM 1´0±1´9. The mean age was 25 years, median 24. Patients with lower MoM were excluded, as it would be expected that only an unreasonable dating error would increase their AFP MoM suf®ciently to become screen positive. For this study, this group was also limited to patients 516 weeks, as its purpose was to evaluate the effects of recalculating one-and two-week changes in cGW during the 15±20-week period for which the panels are valid.
RESULTS AND DISCUSSION
Many obstetricians consider any Down's syndrome risk <1:380 at term to be low risk and those >1:380 to be high risk. All the patients studied here ± with risks at the supplied cGW of <1:500 ± would therefore have been considered at low risk. For the present study, however, recalculated risks have been categorized into three groups: low risk, <1:380; moderate risk, 1:380±1:100; high risk, >1:100. Figure 1 shows the results obtained after recalculation of risks for two patients originally estimated as 17 weeks' cGW. Patient F (Fig. 1a ) was originally reported as having a risk of 1:1980. Even if she were actually as far along as 20 weeks, she would still be in the low-risk category. In contrast, Patient P (Fig. 1b) was at even lower risk (1:2300) if her original cGW of 17 weeks was correct. However, if Patient P were actually 18 weeks, i.e. one week later, her risk would be 1:308, shifting her into the moderate risk category. Her risk would be signi®cantly higher ± 1:70 ± if she were actually 19 weeks.
With regard to the entire group of originally low-risk patients studied here, advancing the original cGW by one week caused risks to increase from between 1´09 and 14´1 times (n=378, median increase 3´18 times, mean increase 3´60 times). Speci®cally, 46 of these originally low-risk patients (12´2%) entered the moderate risk category; the lowest risk in this group had been 1:937. Two (0´5%) became high risk; the lowest risk of this pair had been 1:619.
Advancing the cGW by two weeks caused risks to increase 1´58±60´5 times (n=359, median increase 10´03 times, mean increase 12´04 times). One hundred and thirty-one became moderate risk; the lowest risk in this group had been 1:10 300. Thirty-nine entered the high-risk category; the lowest risk in this group had been as low as 1:3500. No one factor, such as maternal age or insulin dependence, appeared to determine the rate at which risks were changed by changes in dating.
It is evident that if the actual cGW is later than that originally determined, some patients would remain in the same risk category whereas others would clearly be at higher risk for Down's syndrome. It follows that the converse also would be true: if the cGW of a patient determined to be high risk is really less than that originally estimated by even 1±2 weeks, she might actually be at lower risk. Figure 2 shows the original term risk for Patient K, reported to be at 15 weeks. With a risk as originally reported of 1:590, she would be screen negative for Down's syndrome. As an insulin-dependent diabetic, however, her AFP MoM of 2´6 was oNTD screen positive (i.e. MoM >2´0). If she were actually 16 weeks, i.e. one week later, her risk would become 1:160 and AFP MoM 2´2, i.e. she would still be at high risk for oNTD and she also would enter the conventional high-risk category for Down's syndrome. At cGW 17 weeks she would be borderline in oNTD screening with an AFP MoM of 1´9, but the risk of her baby having Down's syndrome would increase to 1:70.
In general, the effect on oNTD screening of changing cGW would be expected to depend on how close the initial MoM was to the screening cutoff. Advancing the cGW by one week allowed ®ve of six non-diabetic patients with original AFP MoM of 2´5±2´9 to become <2´5 and one insulin-dependent patient originally at 2´0 to become <2´0. One non-diabetic with MoM 2´8 required a two-week increase in cGW to become screen negative, as did two insulindependent patients with MoM originally 2´4 and 2´6, respectively. The cGW had to be advanced by two weeks or more for the ®ve patients with AFP MoM above 3´0 to become screen negative.
As might be expected, three patients with AFP MoM 2´4 became screen positive when the cGW was moved back by one week, and 18 patients with AFP MoM 1´8±2´4 became screen positive when the cGW was moved back two weeks. Two of the insulin-dependent patients also became screen positive when the cGW was moved back two weeks. The 52 patients with AFP MoM 1´8 or less would have become screen positive only if their dating error was more than two weeks.
In many cases, one specimen is submitted for analysis and no subsequent, timely recalculations are requested when dating is reassessed by one to two weeks. It is clear that a decision regarding how to proceed with a pregnancy may be made on the basis of an assessment of risks that may be incorrect due to erroneous dating. Dating error may put a patient on either side of a risk cutoff, so that she may be informed that she is at low risk whereas she is actually at higher risk; or she is told she is at high risk and only a subsequent dating reassessment shows that she had been at much lower risk.
Because the chromosome defect test panel provides a statistical assessment of risks based on a number of statistical parameters and, along with oNTD screening, assumes that dating is accurate, and in view of the margin of error of gestational dating, particularly in cases where it is done initially in the second trimester, it may be advisable to report risks routinely not only at the supplied cGW, but for a range of, for example, two weeks. This procedure might avoid undue complacency or concern on the part of both patient and physician.
